J. Randolph Hecht

5.9k total citations · 3 hit papers
78 papers, 4.2k citations indexed

About

J. Randolph Hecht is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, J. Randolph Hecht has authored 78 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in J. Randolph Hecht's work include Colorectal Cancer Treatments and Studies (38 papers), Gastric Cancer Management and Outcomes (21 papers) and Pancreatic and Hepatic Oncology Research (16 papers). J. Randolph Hecht is often cited by papers focused on Colorectal Cancer Treatments and Studies (38 papers), Gastric Cancer Management and Outcomes (21 papers) and Pancreatic and Hepatic Oncology Research (16 papers). J. Randolph Hecht collaborates with scholars based in United States, Spain and Germany. J. Randolph Hecht's co-authors include Rafael G. Amado, William Y. Go, Allen Lee Cohn, Fernando Rivera, Gianpiero Fasola, Meinolf Karthaus, Lee S. Schwartzberg, Jean-Luc Canon, Edith P. Mitchell and Kelly S. Oliner and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

J. Randolph Hecht

76 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

2008 768 citations J. Randolph Hecht et al. Journal of Clinical Oncology profile →
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

2008 644 citations J. Randolph Hecht, Rafael G. Amado et al. Journal of Clinical Oncology profile →
PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

2014 478 citations Lee S. Schwartzberg, Fernando Rivera et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by J. Randolph Hecht

Since Specialization

Citations

This map shows the geographic impact of J. Randolph Hecht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Randolph Hecht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Randolph Hecht more than expected).

Fields of papers citing papers by J. Randolph Hecht

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Randolph Hecht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Randolph Hecht. The network helps show where J. Randolph Hecht may publish in the future.

Co-authorship network of co-authors of J. Randolph Hecht

This figure shows the co-authorship network connecting the top 25 collaborators of J. Randolph Hecht. A scholar is included among the top collaborators of J. Randolph Hecht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Randolph Hecht. J. Randolph Hecht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Amivantamab plus FOLFOX or FOLFIRI in RAS/BRAF wild-type metastatic colorectal cancer: Long-term follow-up from the phase 1b/2 OrigAMI-1 study. 2026 ·Journal of Clinical Oncology ·Eric Xueyu Chen, Rozita Abdul Malik, Yu‐Li Su, Pei Jye Voon, (unknown), Dirk Arnold, J. Randolph Hecht, (unknown), (unknown), (unknown), Sreenivasa R Chandana, (unknown), Sanjib Chowdhury, (unknown), (unknown), Mahesh Daksh, (unknown), Seema Sethi, (unknown)	0
2	Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas 2025 ·Clinical Cancer Research ·Jason J. Luke, Randy F. Sweis, J. Randolph Hecht, Reva Schneider, Mark N. Stein, Talia Golan, Timothy A. Yap, Anuradha Khilnani, Mo Huang, Runchen Zhao, Thomas Jemielita, Sandip Pravin Patel	10
3	Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma 2025 ·The Oncologist ·J. Randolph Hecht, (unknown), Elena Garralda, Hong Jae Chon, Antonia Digklia, Sylvie Rottey, M. Martín Jiménez, Marya Chaney, (unknown), Tatiana Lawrence, (unknown), Ali Hamidi, Jason Chesney	1
4	44P BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy 2024 ·Annals of Oncology ·Grainne M. O’Kane, Jennifer L. Spratlin, D-Y. Oh, Sun Young Rha, Elaine McWhirter, (unknown), Petr Kavan, (unknown), (unknown), Rachel Goodwin, J. Randolph Hecht, (unknown), (unknown), (unknown), Michelle Jones, (unknown), (unknown), Gonzalo Spera, (unknown)	1
5	An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-112 in human leukocyte antigen-C08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation. 2024 ·Journal of Clinical Oncology* ·Salman R. Punekar, Meredith Pelster, Carlos Becerra, J. Randolph Hecht, Andrew Scott Paulson, Patrick Grierson, Maria Pia Morelli, Rom S. Leidner, Mandana Kamgar, Joaquina Baranda, Syed Mohammad Ali Kazmi, Ardaman Shergill, Anne Robinson, Anuradha Patel, (unknown), Jeroen van Heijst, Nathan Demars, Arianne Perez, Sarah S. Cohen, Marwan Fakih	3
6	Zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated MSS/MSI-low metastatic colorectal cancer (mCRC): The randomized phase 3 STELLAR-303 study. 2024 ·Journal of Clinical Oncology ·Anwaar Saeed, Josep Tabernero, Guan Wang, (unknown), (unknown), J. Randolph Hecht	2
7	AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors. 2024 ·Journal of Clinical Oncology* ·(unknown), (unknown), Francis Payumo, E. Gabriela Chiorean, Zhubin Gahvari, J. Randolph Hecht, Michael E. Hurwitz, Rom S. Leidner, Heinz‐Josef Lenz, (unknown), Salman R. Punekar, Adam J. Schoenfeld, Dan Zhao, Markus Vallaster, Dirk Nagorsen	5
8	Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases 2023 ·ESMO Open ·J. Randolph Hecht, Steven S. Raman, Arlene Chan, Kevin Kalinsky, Jean‐François Baurain, M.M. Jimenez, Maria Martinez‐García, Martin D. Berger, Ulrich M. Lauer, (unknown), Alfredo Carrato, Yue Zhang, (unknown), Edward Cha, Alissa Keegan, Sumita Bhatta, (unknown), Aflah Roohullah	22
9	Next-Generation Approaches to Immuno-Oncology in GI Cancers 2023 ·American Society of Clinical Oncology Educational Book ·J. Randolph Hecht, (unknown), Maria Pia Morelli, Gayathri Anandappa, James C. Yang	1
10	STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer (mCRC). 2023 ·Journal of Clinical Oncology ·J. Randolph Hecht, Josep Tabernero, Aparna R. Parikh, Yijia Wang, Zhong Wang, (unknown), (unknown), Anwaar Saeed	4
11	Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy 2022 ·Clinical Cancer Research ·Zev A. Wainberg, Arun S. Singh, Gottfried E. Konecny, Kelly McCann, J. Randolph Hecht, Jonathan W. Goldman, Bartosz Chmielowski, Richard S. Finn, Neil A. O’Brien, Erika von Euw, (unknown), (unknown), (unknown), Meghan Brennan, John A. Glaspy, Dennis J. Slamon	3
12	Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA) 2021 ·Journal of Clinical Oncology ·J. Randolph Hecht, Sara Lonardi, Johanna C. Bendell, Hao‐Wen Sim, Teresa Macarulla, Charles D. Lopez, Eric Van Cutsem, Andrés J. Muñoz Martín, Joon Oh Park, Richard Greil, Hong Wang, Rebecca R. Hozak, Ivelina Gueorguieva, Yong Lin, Sujata Rao, Baek‐Yeol Ryoo	78
13	Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens 2020 ·BMC Cancer ·Zev A. Wainberg, Kynan Feeney, Myung Ah Lee, Andrés J. Muñoz Martín, Antonio Cubillo Gracián, Sara Lonardi, Baek‐Yeol Ryoo, Annie Hung, Yong Lin, Johanna C. Bendell, J. Randolph Hecht	21
14	Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma 2017 ·International Journal of Colorectal Disease ·Fernando Rivera, Meinolf Karthaus, J. Randolph Hecht, Isabel Sevilla, Frédéric Forget, Gianpiero Fasola, Jean-Luc Canon, Xuesong Guan, Gaston Demonty, Lee S. Schwartzberg	79
15	PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer breakdown → 2014 ·Journal of Clinical Oncology ·Lee S. Schwartzberg, Fernando Rivera, Meinolf Karthaus, Gianpiero Fasola, Jean-Luc Canon, J. Randolph Hecht, Hua Yu, Kelly S. Oliner, William Y. Go	478
16	PROGNOSTIC VALUE OF EARLY OBJECTIVE TUMOR RESPONSE (EOTR) TO FIRST LINE SYSTEMIC THERAPY IN METASTATIC COLORECTAL CANCER (MCRC): INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS OF RANDOMIZED TRIALS FROM THE ARCAD DATABASE 2013 ·Asia-Pacific Journal of Clinical Oncology ·Dirkje W. Sommeijer, Qian Shi, (unknown), Katrin Marie Sjoquist, (unknown), Michel Seymour, Jim Cassidy, Richard M. Goldberg, Jean‐Yves Douillard, J. Randolph Hecht, Herbert I. Hurwitz, Christophe Tournigand, Niall C. Tebbutt, Enrique Aranda, John Souglakos, Fairooz F. Kabbinavar, Benoist Chibaudel, Aimery de Gramont, Daniel J. Sargent, John Zalcberg	2
17	Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction 2011 ·British Journal of Cancer ·(unknown), (unknown), Brian DiCarlo, (unknown), Ravi Patel, (unknown), Haijun Wang, Robert M. Elashoff, (unknown), J. Randolph Hecht	63
18	Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer 2007 ·Cancer ·J. Randolph Hecht, Amita Patnaik, Jordan Berlin, Alan P. Venook, Imtiaz A. Malik, Simon Tchekmedyian, Lynn Navale, Rafael G. Amado, Neal J. Meropol	158
19	Panitumumab with Irinotecan/Leucovorin/5-Fluorouracil for First-Line Treatment of Metastatic Colorectal Cancer 2007 ·Clinical Colorectal Cancer ·Jordan Berlin, James Posey, Simon Tchekmedyian, Eddie Hu, David P. Chan, Imtiaz A. Malik, Liqiang Yang, Rafael G. Amado, J. Randolph Hecht	79
20	A Phase III Randomized, Open-Label, Controlled Trial of Chemotherapy and Bevacizumab with or Without Panitumumab in the First-Line Treatment of Patients with Metastatic Colorectal Cancer 2006 ·Clinical Colorectal Cancer ·Zev A. Wainberg, J. Randolph Hecht	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact